MOH 50.24 Molina Healthcare Inc $MOH Hit a 52 week high of

New Post Public Reply Private Reply Replies (0) Message Board

Nov 13, 2014 at 12:56 PM

MOH 50.24 Molina Healthcare Inc $MOH Hit a 52 week high of 50.29 Closing the day 09:44 at 50.24 +0.25 +0.50% With a day low of 49.88 and a total volume of 32,762.

MOH Recent Posts: http://investorshangout.com/Molina-Healthcare-Inc-MOH-51847/

MOH Molina Healthcare Inc Recent Headline News

Insider Trading Alert - CRZO, SEIC And MOH Traded By Insiders
at The Street - Mon Nov 10, 10:00AM CST
Stocks with insider trader activity include CRZO, SEIC and MOH
SEIC: 39.61 (+0.14), CRZO: 48.99 (-1.87), MOH: 49.90 (-0.09)

Insider Buys And Sells: Southern Copper Corp., Microsoft Corporation
Asif Suria - Seeking Alpha - Mon Nov 10, 9:04AM CST
Welcome to edition 229 of Insider Weekends. Insider buying increased last week with insiders buying $90.85 million of stock compared to $63.4 million in the week prior. Selling also increased significantly with insiders selling $2.18 billion of stock...
CCI: 80.62 (+0.11), SCCO: 29.56 (-0.44), STX: 62.20 (-0.12), SONS: 3.54 (-0.07), SIX: 40.63 (-0.24), NS: 60.12 (-0.01), MSFT: 49.54 (+0.76), MOH: 49.90 (-0.09), HUN: 25.27 (+0.38), OZRK: 36.50 (-0.21)

Molina Healthcare Earnings In Retrospect: Up 4.8% in the Last 11 Days (MOH)
Comtex SmarTrend(R) - Mon Nov 10, 8:48AM CST
11 days ago, on October 30th, 2014, Molina Healthcare (NYSE:MOH) reported its earnings. Analysts, on average, expected earnings of $0.42 per share on sales of $2.6 billion. Molina Healthcare actually reported earnings of $0.33 per share on sales of $2.5 billion, missing EPS estimates by $0.09 and missing revenue estimates by $119.5 million. Shares of Molina Healthcare have climbed from $46.52 to $48.75, representing a gain of 4.8% since the company reported earnings 11 days ago.
MOH: 49.90 (-0.09)

Molina Healthcare (MOH) Upgraded From Hold to Buy
at The Street - Mon Nov 10, 8:48AM CST
Molina Healthcare (MOH) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B.
MOH: 49.90 (-0.09)

These Companies Were Election Day Losers
Todd Campbell, The Motley Fool - Motley Fool - Sat Nov 08, 8:35AM CST
Source: Architect of the Capitol Flickr. The votes cast and counted, it appears that private Medicaid insurers including Centene , WellPoint , WellCare and UnitedHealth Group were among the losers. That's because those companies run...
CNC: 97.40 (-0.10), UNH: 96.03 (+0.35), WCG: 69.43 (-0.35), WLP: 127.05 (+0.41), MOH: 49.90 (-0.09)

5 Big Changes for Obamacare in 2015
Sean Williams, The Motley Fool - Motley Fool - Sat Nov 08, 8:26AM CST
Source: White House on Flickr. With mid-term elections now out of the way, consumers can begin turning their attention to two other important factors that roll around this time of year: the holiday season and Obamacare. Sure, buying gifts for...
UNH: 96.03 (+0.35), GIB: 35.62 (+0.76), ACN: 84.34 (+0.22), MOH: 49.90 (-0.09), RGC: 22.64 (+0.21)

DaVita Beats on Q3 Earnings, Down Y/Y; Updates Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 12:50PM CST
DaVita HealthCare Partners Inc. (DVA) reported third-quarter 2014 adjusted operating earnings of $1.01 per share that surpassed the Zacks Consensus Estimate of 91 cents.
DVA: 76.81 (+0.09), GTIV: 19.42 (-0.05), MOH: 49.90 (-0.09), WLP: 127.05 (+0.41)

Humana Posts Lackluster Q3 Earnings, Updates Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:54AM CST
Humana Inc.'s (HUM) third-quarter 2014 operating earnings came in at $1.85 per share, lower than the Zacks Consensus Estimate of $2.01.
AET: 84.72 (+0.20), MOH: 49.90 (-0.09), WLP: 127.05 (+0.41), HUM: 138.57 (+1.32)

Insider Trading Alert - ULTI, MOH And BRCM Traded By Insiders
at The Street - Thu Nov 06, 11:05AM CST
Stocks with insider trader activity include ULTI, MOH and BRCM
ULTI: 153.07 (-1.05), BRCM: 42.19 (+1.04), MOH: 49.90 (-0.09)

Gentiva Earnings Miss Estimates, Up Y/Y; Outlook Reiterated - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 9:00AM CST
Gentiva Health Services, Inc. (GTIV) reported third-quarter 2014 adjusted earnings of 28 cents per share, missing the Zacks Consensus Estimate by a penny.
KND: 20.32 (-0.46), GTIV: 19.42 (-0.05), MOH: 49.90 (-0.09), WLP: 127.05 (+0.41)

Health Net Q3 Earnings Miss By a Penny, Guidance Revised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 2:00PM CST
Health Net's (HNT) third-quarter 2014 operating income of 72 cents per share missed the Zacks Consensus Estimate by a penny and decreased 13% year over year due to higher expenses.
CTSH: 53.27 (+0.03), HNT: 50.28 (+0.83), MOH: 49.90 (-0.09), WLP: 127.05 (+0.41)

Tenet Healthcare Q3 Earnings Beat, Down Y/Y, Guides High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 12:30PM CST
Tenet Healthcare Corp. (THC) reported third-quarter 2014 operating earnings of 36 cents per share that surpassed the Zacks Consensus Estimate of 10 cents.
THC: 47.76 (-0.36), AET: 84.72 (+0.20), MOH: 49.90 (-0.09), WLP: 127.05 (+0.41)

Obamacare's Shocking Effect on Premium Prices
Sean Williams, The Motley Fool - Motley Fool - Sun Nov 02, 7:08AM CST
Source: White House on Flickr. The Affordable Care Act, which is best known in its shorthand form as Obamacare, was developed with a couple of goals in mind. One was obviously to reduce the number of uninsured people in the U.S. The idea here is...
CNC: 97.40 (-0.10), MOH: 49.90 (-0.09)

The 1 Factor That Could Send Obamacare Into a Death Spiral
Sean Williams, The Motley Fool - Motley Fool - Sat Nov 01, 7:38AM CDT
Source: White House on Flickr. Regardless of whether you're a proponent or opponent of the Affordable Care Act, better known as Obamacare, no one can deny that it's changed the healthcare landscape. For some lower-income citizens, it has provided...
CNC: 97.40 (-0.10), WLP: 127.05 (+0.41), MOH: 49.90 (-0.09)

Molina Healthcare ups earnings 113% in Q3
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 3:53PM CDT

MOH: 49.90 (-0.09)

Molina Healthcare (MOH) Marked As A Barbarian At The Gate
at The Street - Fri Oct 31, 9:54AM CDT
Trade-Ideas LLC identified Molina Healthcare (MOH) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
MOH: 49.90 (-0.09)

Molina Healthcare Beats on Q3 Earnings, Lowers Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 9:30AM CDT
Molina Healthcare Inc. (MOH) reported third-quarter 2014 operating earnings of 79 cents per share, handily beating the Zacks Consensus Estimate of 41 cents per share.
CI: 103.02 (+0.91), AET: 84.72 (+0.20), MOH: 49.90 (-0.09), WLP: 127.05 (+0.41)

Molina Healthcare's (MOH) CEO Joseph Molina on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 10:40PM CDT

MOH: 49.90 (-0.09)

Molina misses Street 3Q forecasts
Automated Insights - Thu Oct 30, 4:36PM CDT
LONG BEACH, Calif. (AP) _ Molina Healthcare Inc. (MOH) on Thursday reported third-quarter net income of $16.1 million.
MOH: 49.90 (-0.09)

Molina Healthcare EPS of $0.33
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 4:01PM CDT

MOH: 49.90 (-0.09)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

What to Expect: Your First Therapy Session Insights

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

ASTS Faces Crucial Deadline Amidst Legal Turmoil

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Pathalys' Phase 3 Data Shows Promise for CKD Drug

A Glimpse at Pathalys Pharma's Recent Win This is some groundbreaking stuff emerging from Pathalys Pharma. Their investigational drug, upacicalcet, has just clinched a significant victory in two crucial Phase 3 trials - PATH-1 and PATH-2 - aimed at treating Secondary Hyperparathyroidism (SHPT) in patients with end-stage kidney disease undergoing hemodialysis. With SHPT...

CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

World Young Scientist Summit 2026 in Wenzhou Kicks Off

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

DIRECTV Bags New NHL Deals: Stakes for Sports Fans

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Gildan Faces Lawsuit: Allegations of Deceptive Practices Shake Investors

Gildan's Troubles Unveiled The financial jungle can be a pretty treacherous place, and Gildan Activewear Inc. (NYSE: GIL) just found out how fickle the market can be. An 18.7% nosedive in Gildan's stock price after a securities fraud class action came knocking—if that isn't enough to stir up a hornet’s nest among investors, I don’t know what is. The Catalyst:...

Apalutamide Boosts Outlook for Prostate Cancer Treatment

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

John Wong's Decade as Estate Planning Specialist

One man's legacy isn’t built overnight, especially not in estate planning. And John L. Wong's decade of being a certified specialist by the State Bar of California tells a story of perseverance and grit. Now, at the helm of Modern Wealth Law in Irvine, California, Wong is a name that echoes through the halls of estate planning law with authority and respect. Creating...

Bio-Thera's New Data: A Game Changer for NSCLC?

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...